10 Einträge gefunden

1. Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

   1. Graeser, Monika
   2. Gluz, Oleg
   3. Biehl, Claudia
   4. Ulbrich-Gebauer, Daniel
   5. Christgen, Matthias
   6. Palatty, Jenci
   7. Kuemmel, Sherko

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer:The Neoadjuvant WSG-TP-II Randomized Clinical Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike A
   3. Christgen, Matthias
   4. Kuemmel, Sherko
   5. Holtschmidt, Johannes
   6. Schumacher, Johannes
   7. Hartkopf, Andreas

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
3. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer

   1. Nitz, Ulrike A
   2. Gluz, Oleg
   3. Kümmel, Sherko
   4. Christgen, Matthias
   5. Braun, Michael
   6. Aktas, Bahriye
   7. Lüdtke-Heckenkamp, Kerstin

   2022 - Forschungsinformationssystem des UKE
4. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

   1. Kolberg-Liedtke, Cornelia
   2. Feuerhake, Friedrich
   3. Garke, Madlen
   4. Christgen, Matthias
   5. Kates, Ronald
   6. Grischke, Eva Maria
   7. Forstbauer, Helmut

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma

   1. Christgen, Matthias
   2. Kandt, Leonie Donata
   3. Antonopoulos, Wiebke
   4. Bartels, Stephan
   5. Van Bockstal, Mieke R
   6. Bredt, Martin
   7. Brito, Maria Jose

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
6. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
7. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike
   3. Kolberg-Liedtke, Cornelia
   4. Prat, Aleix
   5. Christgen, Matthias
   6. Kuemmel, Sherko
   7. Mohammadian, Mohammad Parsa

   2022 - Forschungsinformationssystem des UKE
8. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials: Combined analysis from the WSG ADAPT subtrials

   1. Graeser, Monika
   2. Schrading, Simone
   3. Gluz, Oleg
   4. Strobel, Kevin
   5. Würstlein, Rachel
   6. Kümmel, Sherko
   7. Schumacher, Claudia

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

   1. Graeser, Monika
   2. Harbeck, Nadia
   3. Gluz, Oleg
   4. Würstlein, Rachel
   5. Zu Eulenburg, Christine
   6. Schumacher, Claudia
   7. Grischke, Eva-Maria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

    1. Graeser, Monika
    2. Feuerhake, Friedrich
    3. Gluz, Oleg
    4. Volk, Valery
    5. Hauptmann, Michael
    6. Jozwiak, Katarzyna
    7. Christgen, Matthias

    2021 - Forschungsinformationssystem des UKE - frei zugänglich